COVID-19 and corticosteroids: a narrative review.
Inflammopharmacology
; 30(4): 1189-1205, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: covidwho-2258069
ABSTRACT
It has been reported that corticosteroid therapy was effective in the management of severe acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome (MERS), and recently in coronavirus disease 2019 (COVID-19). Corticosteroids are potent anti-inflammatory drugs that mitigate the risk of acute respiratory distress syndrome (ARDS) in COVID-19 and other viral pneumonia, despite a reduction of viral clearance; corticosteroids inhibit the development of cytokine storm and multi-organ damage. The risk-benefit ratio should be assessed for critical COVID-19 patients. In conclusion, corticosteroid therapy is an effective way in the management of COVID-19, it reduces the risk of complications primarily acute lung injury and the development of ARDS. Besides, corticosteroid therapy mainly dexamethasone and methylprednisolone are effective in reducing the severity of COVID-19 and associated comorbidities such as chronic obstructive pulmonary diseases (COPD), rheumatoid arthritis, and inflammatory bowel disease (IBD).
Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Pneumonia Viral
/
Síndrome do Desconforto Respiratório
/
Tratamento Farmacológico da COVID-19
Tipo de estudo:
Estudo prognóstico
/
Revisões
Limite:
Humanos
Idioma:
Inglês
Revista:
Inflammopharmacology
Assunto da revista:
Farmacologia
/
Terapia por Medicamentos
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
S10787-022-00987-z
Similares
MEDLINE
...
LILACS
LIS